They are once-weekly injectable peptides that mimic the body’s gut hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). They slow gastric emptying, curb appetite, improve insulin sensitivity, and—at higher doses—drive significant, sustained weight loss. We currently prescribe Semaglutide (GLP-1 only) and Tirzepatide (dual GLP-1 + GIP).

Clinical trials show average losses of 10-15 % of starting body-weight with Semaglutide and up to 20 % with Tirzepatide over 9-15 months—when paired with nutrition coaching and activity. Results vary by genetics, adherence, and lifestyle change.

Mild, transient nausea, fullness, burping, or constipation. We titrate doses gradually and can add anti-nausea or gut-motility meds if needed. Severe effects (e.g., gallstones, pancreatitis) are rare but monitored.

Yes—studies show safety for 2+ years and counting. Obesity is chronic; many patients keep a maintenance dose to sustain appetite control, similar to how blood-pressure meds are used long-term.

Hunger cues return to baseline within weeks. Without lifestyle changes, ~50 % of lost weight can be regained over 12 months. We coach a phased taper + nutrition plan to minimize rebound.

Moderate alcohol (1 drink/day) is generally safe, but both alcohol and GLP-1s lower blood sugar; excessive drinking increases risk of nausea or hypoglycemia.

Click here to update your Name, email address, or billing information with us!

Your ZOOM link is located in the email that you receive automatically upon booking. Please be sure your email address is up to date with us. Still can’t find it? Click here !